After speaking with management, Jefferies analyst Gena Wang says bluebird bio's development strategy for LentiGlobin is largely unchanged since the Q3 earnings call. Management emphasized that no additional Investigational New Drug filing is required for current programs, Wang tells investors in a research note after the stock closed yesterday down $8.41 to $80.34. Presentations at the American Society of Hematology meeting could provide a meaningful update, but full understanding of LentiGlobin program likely will require longer follow up, Wang points out. She keeps a Buy rating on bluebird with a $108 price target.